Table 2. Participants With Absence of Symptoms at Day 14 by Randomized Treatment Group, Overall and in Prespecified Subgroups.
| Absence of symptoms at day 14, No./total (%) | Prevalence difference, % (95% CI) | Prevalence ratio (95% CI) | P valuea | ||
|---|---|---|---|---|---|
| Azithromycin | Placebo | ||||
| All participants | 66/131 (50) | 35/70 (50) | 0 (−14 to 15) | 1.01 (0.76-1.39) | >.99 |
| By age, y | |||||
| ≤60 | 61/121 (50) | 31/62 (50) | 0 (−15 to 16) | .99 | |
| >60 | 5/10 (50) | 4/8 (50) | 0 (−46 to 46) | ||
| By baseline COVID-19 symptomsb | |||||
| Asymptomatic | 9/10 (90) | 3/4 (75) | 15 (−46 to 76) | .52 | |
| Symptomatic | 57/120 (48) | 32/66 (48) | −1 (−17 to 15) | ||
a
Permutation test P value, 10 000 replicates (primary analysis) or P value for interaction on the additive scale (subgroup analyses), estimated with a linear-binomial model.
b
A single participant in the azithromycin group did not have baseline symptom information.